Compare ProShares UltraPro QQQ ETF (TQQQ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro QQQ ETF vs Viatris Inc — how do they compare? ProShares UltraPro QQQ ETF trades at $71.07, while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while ProShares UltraPro QQQ ETF pays none, and Viatris Inc is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| TQQQ | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $87.22 | $17.39 |
52-Week Low | $37.89 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TQQQ trades at $67.65, up 0.18% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF's structure amplifies daily Nasdaq-100 returns, yet financial ratios are unavailable as it's a leveraged fund tracking an index. Recent news highlights volatility risks, with articles warning of amplified losses during market downturns despite historical gains in bull markets.
Outlook remains cautious due to leverage decay and bearish technicals; opportunities exist for tactical traders during rebounds, but risks include heightened volatility and structural costs. Long-term holders face potential erosion from daily rebalancing, especially in sideways or declining markets.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
